Skip to main content
SpringerLink
Log in

Infantile Spasms: Pharmacotherapy Challenges

  • Reference work entry
  • First Online:
NeuroPsychopharmacotherapy

  • 27 Accesses

Abstract

Infantile spasms (IS, epileptic spasms during infancy) represent a unique entity among epilepsy syndromes. Both its clinical picture (brief spastic seizures) and electrographic signature (EEG suppression during the spasms and chaotic pattern of large-amplitude asynchronous waves = hypsarrhythmia in between the spasms) emphasize a special status of this epilepsy syndrome. The syndrome most often develops in infants between 3–12 months of age and is frequently associated with developmental arrest or even regress (West syndrome). In addition to the peculiar electroclinical syndrome, the treatments of infantile spasms are also dissimilar to treatments of other epilepsy syndromes. First-line treatments include adrenocorticotropin, corticosteroids, and vigabatrin. However, long-term efficacy of either of these treatments does not exceed 55% and all of them have serious adverse effects. Thus, new approaches (using the old drugs) or novel treatments are investigated. Recently a combination of hormonal treatments with vigabatrin has been shown to be more effective than either of its components. Second-line treatments such as topiramate, ketogenic diet, pyridoxin, zonisamide, valproate, cannabidiol, mTOR inhibitors, clobazam, and felbamate expand the therapeutic armamentarium, however there is insufficient evidence that they are as effective as standard treatments. Experimental treatment approaches aim to eliminate adverse effects of vigabatrin (peripheral retinopathy) by concurrent use of NKCC2 inhibitors such as bumetanide. Others focus on individual genetic causes out of many associated with infantile spasms and attempt to revert phenotypic outcomes of these mutations. An example here is early neonatal estradiol administration improving density of interneurons impaired by triplet repeat expansion in the ARX gene. However, these approaches do not have general therapeutic validity and can be used only for patients with specific identified gene mutations as adverse effects of such treatments if not applied properly can be fierce. Hence, the IS still require painstaking search for novel treatments aligned with many different genetic mutations, in some we already may know the mechanisms, in some we are still searching. This laborious approach will eventually lead to precision and personalized disease modifying treatments in patients suffering from IS.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 949.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 1,399.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Auvin S, Walker L, Gallentine W, Jozwiak S, Tombini M, Sills GJ. Prospective clinical trials to investigate clinical and molecular biomarkers. Epilepsia. 2017;58(Suppl 3):20–6.

    CAS  PubMed  Google Scholar 

  • Baram TZ, Mitchell WG, Tournay A, Snead OC, Hanson RA, Horton EJ. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study. Pediatrics. 1996;97(3):375–9.

    CAS  PubMed  Google Scholar 

  • Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia. 2010;51(4):676–85.

    PubMed  Google Scholar 

  • Berg AT, Wusthoff C, Shellhaas RA, Loddenkemper T, Grinspan ZM, Saneto RP, et al. Immediate outcomes in early life epilepsy: a contemporary account. Epilepsy Behav. 2019;97:44–50.

    PubMed  PubMed Central  Google Scholar 

  • Bosetti F, Koenig JI, Ayata C, Back SA, Becker K, Broderick JP, et al. Translational stroke research: vision and opportunities. Stroke. 2017;48(9):2632–7.

    PubMed  PubMed Central  Google Scholar 

  • Brunson KL, Eghbal-Ahmadi M, Baram TZ. How do the many etiologies of west syndrome lead to excitability and seizures? The corticotropin releasing hormone excess hypothesis. Brain Dev. 2001;23(7):533–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Camposano SE, Major P, Halpern E, Thiele EA. Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. Epilepsia. 2008;49(7):1186–91.

    CAS  PubMed  Google Scholar 

  • Chang YH, Chen C, Chen SH, Shen YC, Kuo YT. Effectiveness of corticosteroids versus adrenocorticotropic hormone for infantile spasms: a systematic review and meta-analysis. Ann Clin Transl Neurol. 2019;6(11):2270–81.

    PubMed  PubMed Central  Google Scholar 

  • Choudhary A, Charkhad B, Barrett K, Scantlebury M, ed. Effectiveness of the ketogenic diet for the control of seizures in the triple-hit model of the infantile spasms syndrome. American Epilepsy Society Annual Meeting; 2018 Published to Web: 11/05/2018 07:00 pm; New Orleans.

    Google Scholar 

  • D’Alonzo R, Rigante D, Mencaroni E, Esposito S. West syndrome: a review and guide for paediatricians. Clin Drug Investig. 2018;38(2):113–24.

    PubMed  Google Scholar 

  • Darke K, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Lux AL, et al. Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial. Arch Dis Child. 2010;95(5):382–6.

    PubMed  Google Scholar 

  • Dozieres-Puyravel B, Nasser H, Bellavoine V, Ilea A, Delanoe C, Auvin S. Felbamate for infantile spasms syndrome resistant to first-line treatments. Dev Med Child Neurol. 2020;62(5):581–6.

    PubMed  Google Scholar 

  • Dracopoulos A, Widjaja E, Raybaud C, Westall CA, Snead OC. Vigabatrin-associated reversible MRI signal changes in patients with infantile spasms. Epilepsia. 2010;51(7):1297–304.

    PubMed  Google Scholar 

  • Fox JR, Guido-Estrada N, Williams K, Jarrar R. Outcomes among patients with infantile spasms treated with hormonal therapy and adjuvant topiramate versus hormonal therapy alone. Epileptic Disord. 2020;22(1):33–8.

    Google Scholar 

  • Franz DN, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, et al. Everolimus for treatment-refractory seizures in TSC: extension of a randomized controlled trial. Neurol Clin Pract. 2018;8(5):412–20.

    PubMed  PubMed Central  Google Scholar 

  • French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10056):2153–63.

    CAS  PubMed  Google Scholar 

  • Gibbs FA, Gibbs EL. Atlas of electroencephalography. Cambridge, MA: Addison-Wesley; 1952.

    Google Scholar 

  • Gipson TT, Gerner G, Srivastava S, Poretti A, Vaurio R, Hartman A, et al. Early neurodevelopmental screening in tuberous sclerosis complex: a potential window of opportunity. Pediatr Neurol. 2014;51(3):398–402.

    PubMed  PubMed Central  Google Scholar 

  • Glauser TA, Clark PO, Strawsburg R. A pilot study of topiramate in the treatment of infantile spasms. Epilepsia. 1998;39(12):1324–8.

    CAS  PubMed  Google Scholar 

  • Go CY, Mackay MT, Weiss SK, Stephens D, Adams-Webber T, Ashwal S, et al. Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2012;78(24):1974–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Gonzalez-Giraldo E, Stafstrom CE, Stanfield AC, Kossoff EH. Treating infantile spasms with high-dose oral corticosteroids: a retrospective review of 87 children. Pediatr Neurol. 2018;87:30–5.

    PubMed  Google Scholar 

  • Gowda VK, Narayanaswamy V, Shivappa SK, Benakappa N, Benakappa A. Corticotrophin-ACTH in comparison to prednisolone in west syndrome – a randomized study. Indian J Pediatr. 2019;86(2):165–70.

    PubMed  Google Scholar 

  • Hahn J, Lee H, Kang HC, Lee JS, Kim HD, Kim SH, et al. Clobazam as an adjunctive treatment for infantile spasms. Epilepsy Behav. 2019;95:161–5.

    PubMed  Google Scholar 

  • Hamano SI, Nagai T, Matsuura R, Hirata Y, Ikemoto S, Oba A, et al. Treatment of infantile spasms by pediatric neurologists in Japan. Brain Dev. 2018;40(8):685–92.

    PubMed  Google Scholar 

  • Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane Database Syst Rev. 2013;6:CD001770.

    Google Scholar 

  • Hani AJ, Mikati MA. Current and emerging therapies of severe epileptic encephalopathies. Semin Pediatr Neurol. 2016;23(2):180–6.

    PubMed  Google Scholar 

  • Hara K, Watanabe K, Miyazaki S, Hakamada S, Yamada H, Nakamura S. Apparent brain atrophy and subdural hematoma following ACTH therapy. Brain Dev. 1981;3(1):45–9.

    CAS  PubMed  Google Scholar 

  • Hengel H, Bosso-Lefevre C, Grady G, Szenker-Ravi E, Li H, Pierce S, et al. Loss-of-function mutations in UDP-glucose 6-dehydrogenase cause recessive developmental epileptic encephalopathy. Nat Commun. 2020;11(1):595.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Hong AM, Turner Z, Hamdy RF, Kossoff EH. Infantile spasms treated with the ketogenic diet: prospective single-center experience in 104 consecutive infants. Epilepsia. 2010;51(8):1403–7.

    PubMed  Google Scholar 

  • Frost JD Jr, Hrachovy RA. Infantile spasms: diagnosis, management and prognosis. Boston/Dordrecht/London: Kluwer Academic; 2003.

    Google Scholar 

  • Hussain SA. Treatment of infantile spasms. Epilepsia Open. 2018;3(Suppl 2):143–54.

    PubMed  PubMed Central  Google Scholar 

  • Hussain SA, Shinnar S, Kwong G, Lerner JT, Matsumoto JH, Wu JY, et al. Treatment of infantile spasms with very high dose prednisolone before high dose adrenocorticotropic hormone. Epilepsia. 2014;55(1):103–7.

    CAS  PubMed  Google Scholar 

  • Hussain SA, Zhou R, Jacobson C, Weng J, Cheng E, Lay J, et al. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy Behav. 2015;47:138–41.

    PubMed  Google Scholar 

  • Hussain SA, Shin JH, Shih EJ, Murata KK, Sewak S, Kezele ME, et al. Limited efficacy of the ketogenic diet in the treatment of highly refractory epileptic spasms. Seizure. 2016;35:59–64.

    PubMed  Google Scholar 

  • Hussain SA, Lay J, Cheng E, Weng J, Sankar R, Baca CB. Recognition of infantile spasms is often delayed: the ASSIST study. J Pediatr. 2017a;190:215–21 e1.

    PubMed  Google Scholar 

  • Hussain SA, Tsao J, Li M, Schwarz MD, Zhou R, Wu JY, et al. Risk of vigabatrin-associated brain abnormalities on MRI in the treatment of infantile spasms is dose-dependent. Epilepsia. 2017b;58(4):674–82.

    CAS  PubMed  Google Scholar 

  • Hussain SA, Schmid E, Peters JM, Goyal M, Bebin EM, Northrup H, et al. High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex. Epilepsy Res. 2018;148:1–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Hussain SA, Navarro M, Heesch J, Ji M, Asilnejad B, Peters H, et al. Limited efficacy of zonisamide in the treatment of refractory infantile spasms. Epilepsia Open. 2020;5(1):121–6.

    PubMed  PubMed Central  Google Scholar 

  • Jensen FE, inventor; Children s Medical Center Corp, assignee. Combination therapies: inhibitors of GABA transaminase and NKCC1. United States. 2014 2014-09-02.

    Google Scholar 

  • Kayyali HR, Gustafson M, Myers T, Thompson L, Williams M, Abdelmoity A. Ketogenic diet efficacy in the treatment of intractable epileptic spasms. Pediatr Neurol. 2014;50(3):224–7.

    PubMed  Google Scholar 

  • Knupp KG, Coryell J, Nickels KC, Ryan N, Leister E, Loddenkemper T, et al. Response to treatment in a prospective national infantile spasms cohort. Ann Neurol. 2016a;79(3):475–84.

    PubMed  PubMed Central  Google Scholar 

  • Knupp KG, Leister E, Coryell J, Nickels KC, Ryan N, Juarez-Colunga E, et al. Response to second treatment after initial failed treatment in a multicenter prospective infantile spasms cohort. Epilepsia. 2016b;57(11):1834–42.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kossoff EH, Pyzik PL, McGrogan JR, Vining EP, Freeman JM. Efficacy of the ketogenic diet for infantile spasms. Pediatrics. 2002;109(5):780–3.

    PubMed  Google Scholar 

  • Kossoff EH, Hartman AL, Rubenstein JE, Vining EP. High-dose oral prednisolone for infantile spasms: an effective and less expensive alternative to ACTH. Epilepsy Behav. 2009;14(4):674–6.

    PubMed  Google Scholar 

  • Kossoff EH, Zupec-Kania BA, Auvin S, Ballaban-Gil KR, Christina Bergqvist AG, Blackford R, et al. Optimal clinical management of children receiving dietary therapies for epilepsy: updated recommendations of the International Ketogenic Diet Study Group. Epilepsia Open. 2018;3(2):175–92.

    PubMed  PubMed Central  Google Scholar 

  • Lux AL, Osborne JP. A proposal for case definitions and outcome measures in studies of infantile spasms and west syndrome: consensus statement of the West Delphi group. Epilepsia. 2004;45(11):1416–28.

    PubMed  Google Scholar 

  • Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, et al. The United Kingdom infantile spasms study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet. 2004;364(9447):1773–8.

    CAS  PubMed  Google Scholar 

  • Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, et al. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol. 2005;4(11):712–7.

    CAS  PubMed  Google Scholar 

  • Mackay MT, Weiss SK, Adams-Webber T, Ashwal S, Stephens D, Ballaban-Gill K, et al. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology. 2004;62(10):1668–81.

    CAS  PubMed  Google Scholar 

  • Mehta D, Jackson R, Paul G, Shi J, Sabbagh M. Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010–2015. Expert Opin Investig Drugs. 2017;26(6):735–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Meikle L, Pollizzi K, Egnor A, Kramvis I, Lane H, Sahin M, et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci. 2008;28(21):5422–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Mohamed BP, Scott RC, Desai N, Gutta P, Patil S. Seizure outcome in infantile spasms–a retrospective study. Epilepsia. 2011;52(4):746–52.

    PubMed  Google Scholar 

  • Mu C, Choudhary A, Charkhad B, Barrett K, Shearer J, Rho JM, et al. The ketogenic diet alters the gut microbiome in the triple-hit rodent model of infantile spasms. American Epilepsy Society Annual Meeting; 2018 Published to web: 11/05/2018 07:00 pm; New Orleans.

    Google Scholar 

  • Nadig PL, Sahu JK, Suthar R, Saini A, Sankhyan N. Topiramate as an Adjunct in the Management of West Syndrome. Indian J Pediatr. 2020;87(1):6–11.

    Google Scholar 

  • Nordli DR Jr, Kuroda MM, Carroll J, Koenigsberger DY, Hirsch LJ, Bruner HJ, et al. Experience with the ketogenic diet in infants. Pediatrics. 2001;108(1):129–33.

    PubMed  Google Scholar 

  • O’Callaghan FJ, Edwards SW, Alber FD, Hancock E, Johnson AL, Kennedy CR, et al. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol. 2017;16(1):33–42.

    PubMed  Google Scholar 

  • O’Callaghan FJK, Edwards SW, Alber FD, Cortina Borja M, Hancock E, Johnson AL, et al. Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial. Lancet Child Adolesc Health. 2018;2(10):715–25.

    PubMed  Google Scholar 

  • Ohya T, Nagai T, Araki Y, Yanagawa T, Tanabe T, Iyoda K, et al. A pilot study on the changes in immunity after ACTH therapy in patients with west syndrome. Brain Dev. 2009;31(10):739–43.

    PubMed  Google Scholar 

  • Olivetti PR, Maheshwari A, Noebels JL. Neonatal estradiol stimulation prevents epilepsy in Arx model of X-linked infantile spasms syndrome. Sci Transl Med. 2014;6(220):220ra12.

    PubMed  PubMed Central  Google Scholar 

  • Osborne JP, Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, et al. The underlying etiology of infantile spasms (west syndrome): information from the United Kingdom Infantile Spasms Study (UKISS) on contemporary causes and their classification. Epilepsia. 2010;51(10):2168–74.

    PubMed  Google Scholar 

  • Ounissi M, Rodrigues C, Bienayme H, Duhamel P, Pons G, Dulac O, et al. Proposition of a minimal effective dose of vigabatrin for the treatment of infantile spasms using pediatric and adult pharmacokinetic data. J Clin Pharmacol. 2019;59(2):177–88.

    CAS  PubMed  Google Scholar 

  • Parasrampuria DA, Benet LZ, Sharma A. Why drugs fail in late stages of development: case study analyses from the last decade and recommendations. AAPS J. 2018;20(3):46.

    PubMed  Google Scholar 

  • Partikian A, Mitchell WG. Major adverse events associated with treatment of infantile spasms. J Child Neurol. 2007;22(12):1360–6.

    PubMed  Google Scholar 

  • Pavone P, Striano P, Falsaperla R, Pavone L, Ruggieri M. Infantile spasms syndrome, west syndrome and related phenotypes: what we know in 2013. Brain Dev. 2014;36(9):739–51.

    PubMed  Google Scholar 

  • Pearl PL, Vezina LG, Saneto RP, McCarter R, Molloy-Wells E, Heffron A, et al. Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia. 2009;50(2):184–94.

    CAS  PubMed  Google Scholar 

  • Pearl PL, Poduri A, Prabhu SP, Harini C, Goldstein R, Atkinson RM, et al. White matter spongiosis with vigabatrin therapy for infantile spasms. Epilepsia. 2018;59(4):e40–e4.

    CAS  PubMed  Google Scholar 

  • Peltzer B, Alonso WD, Porter BE. Topiramate and adrenocorticotropic hormone (ACTH) as initial treatment for infantile spasms. J Child Neurol. 2009;24(4):400–5.

    PubMed  PubMed Central  Google Scholar 

  • Perucca P, Perucca E. Identifying mutations in epilepsy genes: impact on treatment selection. Epilepsy Res. 2019;152:18–30.

    CAS  PubMed  Google Scholar 

  • Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 2013;29(3):574–7.

    PubMed  PubMed Central  Google Scholar 

  • Rajaraman RR, Lay J, Alayari A, Anderson K, Sankar R, Hussain SA. Prevention of infantile spasms relapse: zonisamide and topiramate provide no benefit. Epilepsia. 2016;57(8):1280–7.

    CAS  PubMed  Google Scholar 

  • Riikonen R. Infantile spasms: therapy and outcome. J Child Neurol. 2004;19(6):401–4.

    PubMed  Google Scholar 

  • Riikonen R. Recent advances in the pharmacotherapy of infantile spasms. CNS Drugs. 2014;28(4):279–90.

    CAS  PubMed  Google Scholar 

  • Riikonen R. Long-term outcome in children with infantile spasms treated with vigabatrin: a cohort of 180 patients. Epilepsia. 2015;56(5):807–9.

    PubMed  Google Scholar 

  • Riikonen R, Donner M. ACTH therapy in infantile spasms: side effects. Arch Dis Child. 1980;55(9):664–72.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Riikonen R, Rener-Primec Z, Carmant L, Dorofeeva M, Hollody K, Szabo I, et al. Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study. Dev Med Child Neurol. 2015;57(1):60–7.

    PubMed  Google Scholar 

  • Scheffer IE, Wallace RH, Phillips FL, Hewson P, Reardon K, Parasivam G, et al. X-linked myoclonic epilepsy with spasticity and intellectual disability: mutation in the homeobox gene ARX. Neurology. 2002;59(3):348–56.

    CAS  PubMed  Google Scholar 

  • Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512–21.

    PubMed  PubMed Central  Google Scholar 

  • Shbarou R, Mikati MA. The expanding clinical spectrum of genetic pediatric epileptic encephalopathies. Semin Pediatr Neurol. 2016;23(2):134–42.

    PubMed  Google Scholar 

  • Siehr MS, Massey CA, Noebels JL. Arx expansion mutation perturbs cortical development by augmenting apoptosis without activating innate immunity in a mouse model of X-linked infantile spasms syndrome. Dis Model Mech. 2020;13(3)

    Google Scholar 

  • Snead OCD, Benton JW, Myers GJ. ACTH and prednisone in childhood seizure disorders. Neurology. 1983;33(8):966–70.

    PubMed  Google Scholar 

  • Snead OCD, Benton JW Jr, Hosey LC, Swann JW, Spink D, Martin D, et al. Treatment of infantile spasms with high-dose ACTH: efficacy and plasma levels of ACTH and cortisol. Neurology. 1989;39(8):1027–31.

    PubMed  Google Scholar 

  • Song JM, Hahn J, Kim SH, Chang MJ. Efficacy of treatments for infantile spasms: a systematic review. Clin Neuropharmacol. 2017;40(2):63–84.

    PubMed  Google Scholar 

  • Sorel L, Dusaucy-Bauloye A. A propos de 21 cas d’hypsarythmie de Gibbs. Son traitement spectaculaire par l’ACTH. Acta Neurol Belg. 1958;58:130–41.

    CAS  Google Scholar 

  • Stockler S, Plecko B, Gospe SM Jr, Coulter-Mackie M, Connolly M, van Karnebeek C, et al. Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol Genet Metab. 2011;104(1–2):48–60.

    CAS  PubMed  Google Scholar 

  • Suleiman J, Brenner T, Gill D, Troedson C, Sinclair AJ, Brilot F, et al. Immune-mediated steroid-responsive epileptic spasms and epileptic encephalopathy associated with VGKC-complex antibodies. Dev Med Child Neurol. 2011;53(11):1058–60.

    PubMed  Google Scholar 

  • Suzuki Y. Zonisamide in west syndrome. Brain Dev. 2001;23(7):658–61.

    CAS  PubMed  Google Scholar 

  • Takata A, Nakashima M, Saitsu H, Mizuguchi T, Mitsuhashi S, Takahashi Y, et al. Comprehensive analysis of coding variants highlights genetic complexity in developmental and epileptic encephalopathy. Nat Commun. 2019;10(1):2506.

    PubMed  PubMed Central  Google Scholar 

  • van der Poest Clement EA, Sahin M, Peters JM. Vigabatrin for epileptic spasms and tonic seizures in tuberous sclerosis complex. J Child Neurol. 2018;33(8):519–24.

    PubMed  Google Scholar 

  • Vanhatalo S, Paakkonen L, Nousiainen I. Visual field constriction in children treated with vigabatrin. Neurology. 1999;52(8):1713–4.

    CAS  PubMed  Google Scholar 

  • Vanhatalo S, Nousiainen I, Eriksson K, Rantala H, Vainionpaa L, Mustonen K, et al. Visual field constriction in 91 Finnish children treated with vigabatrin. Epilepsia. 2002;43(7):748–56.

    PubMed  Google Scholar 

  • Velíšek L, Velíšková J. Modeling epileptic spasms during infancy: are we heading for the treatment yet? Pharmacol Ther. 2020;212:107578.

    PubMed  PubMed Central  Google Scholar 

  • Vigevano F, Cilio MR. Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study. Epilepsia. 1997;38(12):1270–4.

    CAS  PubMed  Google Scholar 

  • Wang Q, Liu Z, Lin Z, Zhang R, Lu Y, Su W, et al. De novo germline mutations in SEMA5A associated with infantile spasms. Front Genet. 2019;10:605.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Wanigasinghe J, Arambepola C, Ranganathan SS, Sumanasena S. Randomized, single-blind, parallel clinical trial on efficacy of oral prednisolone versus intramuscular corticotropin: a 12-month assessment of spasm control in west syndrome. Pediatr Neurol. 2017;76:14–9.

    PubMed  Google Scholar 

  • Weaving LS, Christodoulou J, Williamson SL, Friend KL, McKenzie OL, Archer H, et al. Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation. Am J Hum Genet. 2004;75(6):1079–93.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Weber A, Cole JW, Mytinger JR. Infantile spasms respond poorly to topiramate. Pediatr Neurol. 2015;53(2):130–4.

    PubMed  Google Scholar 

  • Widjaja E, Go C, McCoy B, Snead OC. Neurodevelopmental outcome of infantile spasms: a systematic review and meta-analysis. Epilepsy Res. 2015;109:155–62.

    PubMed  Google Scholar 

  • Yanai S, Hanai T, Narazaki O. Treatment of infantile spasms with zonisamide. Brain Dev. 1999;21(3):157–61.

    CAS  PubMed  Google Scholar 

  • Yeh HR, Kim MJ, Ko TS, Yum MS, You SJ. Short-term outcome of intravenous methylprednisolone pulse therapy in patients with infantile spasms. Pediatr Neurol. 2017;71:50–5.

    PubMed  Google Scholar 

  • Yi Z, Wu H, Yu X, Zha J, Chen H, Chen Y, et al. High-dose prednisone therapy for infantile spasms and late-onset epileptic spasms in China: The addition of topiramate provides no benefit. Seizure. 2019;71:174–8.

    Google Scholar 

  • Yum MS, Ko TS. Zonisamide in west syndrome: an open label study. Epileptic Disord. 2009;11(4):339–44.

    PubMed  Google Scholar 

  • Yum MS, Lee EH, Ko TS. Vigabatrin and mental retardation in tuberous sclerosis: infantile spasms versus focal seizures. J Child Neurol. 2013;28(3):308–13.

    PubMed  Google Scholar 

  • Zafeiriou DI, Kontopoulos EE, Tsikoulas IG. Adrenocorticotropic hormone and vigabatrin treatment of children with infantile spasms underlying cerebral palsy. Brain Dev. 1996;18(6):450–2.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Cell Biology & Anatomy, Obstetrics & Gynecology, and Neurology, New York Medical College, Valhalla, NY, USA

    Jana Velíšková

  2. Departments of Cell Biology & Anatomy, Pediatrics, and Neurology, New York Medical College, Valhalla, NY, USA

    Libor Velíšek

Authors
  1. Jana Velíšková
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Libor Velíšek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Libor Velíšek .

Editor information

Editors and Affiliations

  1. Clinic and Policlinic for Psychiatry, Psychosomatics and Psychotherapy, University Hospital Wuerzburg, Wuerzburg, Germany

    Peter Riederer

  2. Institute of Psychological Medicine (IPM), Soyen, Germany

    Gerd Laux

  3. Centre for Research Promotion and Support, Fujita Health University, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

  4. Center Translational Res Neurol Diseases, Dalian Med Uni Shanghai Inst Health Sc Center Translational Res Neurol Diseases, Dalian, China

    Weidong Le

  5. Würzburg, Germany

    Christian Riederer

Section Editor information

  1. Center of Mental Health, Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital Würzburg, Würzburg, Germany

    Peter Riederer

  2. Center for Research Promotion and Support, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Velíšková, J., Velíšek, L. (2022). Infantile Spasms: Pharmacotherapy Challenges. In: Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-030-62059-2_435

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-62059-2_435

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-62058-5

  • Online ISBN: 978-3-030-62059-2

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation